The $2.3M patent purchase is small relative to the $16M market cap but represents a meaningful cash outlay for a micro-cap apparel SCM company pivoting into biotech. Monitor closing conditions and any subsequent strategic investment in Future Biotechnology Group, which could be larger.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 5 $1.59entry
- T+1 · 11d ago −17.61%α −17.92% · $1.31
- T+5 · 5d ago −1.57%α −4.86% · $1.57
- T+8 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ping An Biomedical entered a definitive agreement to acquire three tumor cell-related medical technology patents from Future Biotechnology Group for $2.3 million. The acquisition is positioned as a long-term capacity-building move, not a near-term revenue driver, and the company continues to advance negotiations for a strategic investment in the seller.
Key Facts
- Definitive purchase agreement for three tumor cell-related patents at $2.3 million
- Patents cover oncology diagnosis/treatment, cell detection/bioengineering, biomarker/DNA probe technologies
- Company states the acquisition is not a near-term revenue driver but a capacity-building move
- Separately, negotiations continue for a proposed strategic investment in Future Biotechnology Group
- Company's primary business is apparel supply chain management; healthcare/biomedical is a newer strategic direction
Financial Impact
Cash consideration of $2.3 million; represents ~14% of $16M market cap
Risk Factors
- No near-term revenue expected from the acquired patents; commercialization path is staged and subject to regulatory approvals
- Company's primary business is apparel SCM, not biotech; execution risk in a new technology area
- Cash burn risk: $2.3M is material for a $16M market cap company
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-116144 |
| Document: ea0311054-6k_pingan.htm | 0001213900-26-116144 |
| Document: 0001213900-26-116144-index-headers.html | 0001213900-26-116144 |
| Document: 0001213900-26-116144-index.html | 0001213900-26-116144 |
| Document: 0001213900-26-116144.txt | 0001213900-26-116144 |
| Earnings Context (Synthetic; results releases only) | 0001213900-26-116144 |
Track record
12 reports on PASW
2 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +71.15% at T+5 after the Oct 30, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 17, 2026today 6-K Neutral 4/10 Entry $1.41 Now $1.44 +1.94% settles Nov 19
- Nov 12, 20265d ago EFFECT Neutral 3/10 Entry $1.57 to $1.53 Now $1.44 −7.99% ▼ −2.24% −1.87% vs SPY
- Nov 5, 202612d ago 6-K Neutral 3/10 Viewing Entry $1.59 to $1.31 Now $1.44 −9.43% ▼ −17.61% −17.92% vs SPY
- Oct 30, 202618d ago 6-K Bearish 6/10 Entry $4.68 to $4.96 Now $1.44 +69.23% ▼ −5.98% −5.68% vs SPY
- Oct 26, 202622d ago 6-K Neutral 4/10 Entry $4.48 to $4.88 Now $1.44 −67.86% ▲ +8.93% +8.37% vs SPY
- Oct 22, 202626d ago 6-K Bearish 5/10 Entry $4.76 to $4.48 Now $1.44 +69.75% ▲ +5.88% +6.59% vs SPY
- Oct 22, 202626d ago Press Release Neutral 3/10 Entry $0.1340 to $0.1190 Now $1.44 +974.63% ▼ −11.19% −10.67% vs SPY
- Oct 21, 202627d ago 6-K Neutral 3/10 Entry $3.68 to $5.40 Now $1.44 −60.87% ▲ +46.85% +48.03% vs SPY
- Sep 11, 20269w ago 6-K Bearish 6/10 Entry $0.1380 to $0.1367 Now $1.44 −943.48% ▲ +0.94% +0.50% vs SPY
- Jul 20, 202617w ago 6-K Neutral 4/10 Entry $0.1459 to $0.1467 Now $1.44 +886.98% ▲ +0.55% −0.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers